Thank you.
Very briefly, the first is on the actual submission and approval of a product before it hits the market. We are in close collaboration with our international colleagues. There are some complexities with that where the drug companies don't always submit at the same time to different jurisdictions. So it may be in Canada before the U.S., it may be in the U.S. before Canada, and there can actually be differences between the submissions from country to country, which the companies do for their own specific reasons.
However, once that's said, when we can, we definitely do collaborate. We look at where they're the same and where they're different. Once the product is on the market, absolutely, we are collaborating on signal detection, so adverse events are shared globally to find out if there are issues. When there are problems, they are shared internationally.
As the deputy pointed out, there are numerous examples where we have gone before the U.S., where our review might actually say—to your point—the problem that the FDA found was already on the label in Canada, and there was no need to adjust the product in Canada. We have examples where we were 10 years ahead of the U.S. in terms of what our label had on it compared to what they did, and vice versa. So there are instances where we pull product, and they don't; we issue label updates, and they don't.